

Tripping up addiction: The use of psychedelic drugs in the treatment of problematic drug and alcohol use

Short Title: *Illicit drugs in the treatment of addiction*

Celia Morgan ^{1,3}, Amy McAndrew¹, Tobias Stevens¹, David Nutt², Will Lawn^{1,3}

1. *Psychopharmacology and Addiction Research Centre, University of Exeter, UK*
2. *Centre for Neuropsychopharmacology, Imperial College London, UK*
3. *Clinical Psychopharmacology Unit, University College London, UK*

Address Correspondence to:

*Celia Morgan
Psychopharmacology and Addiction Research Centre
Washington Singer Laboratory
University of Exeter
Perry Road, Exeter
Devon
UK EX4 4QG*

Key words: addiction, psychedelics, ketamine, ibogaine, ayahuasca, LSD , psilocybin, neurogenesis,

Highlights:

- *Psilocybin may reduce alcohol and tobacco use in addicted samples.*
- *Ibogaine and ayahuasca have shown promise in the treatment of various addictions through observational studies.*
- *Ketamine has been used to treat alcohol dependence and reduces cocaine self-administration in the human laboratory.*
- *Randomised controlled trials are greatly needed to further test the efficacy of all of these compounds.*
- *Psychedelic drugs may have their therapeutic qualities due to anti-depressant effects, stimulating neuroplasticity and long-term psychological changes.*

Abstract

Psychedelic drugs have been used as treatments in indigenous cultures for thousands of years. Yet, due to their legal status, there has been limited scientific research into the therapeutic potential of these compounds for psychiatric disorders. In the absence of other effective treatments however, researchers have begun again to systematically investigate such compounds and there is now evidence pointing to the use of psychedelic drugs in the treatment of addiction. In this review we focus on human evidence for the effectiveness of preparations used by indigenous cultures in the Amazon (ayahuasca) and Africa (ibogaine) and worldwide (psilocybin), and more recently synthesised drugs such as the serotonergic hallucinogen LSD and the dissociative anaesthetic ketamine. Potential mechanisms explored are anti-depressant effects, changes in neuroplasticity and existential psychological effects of these drugs.

“If, therefore, under LSD we can have a temporary reduction, so that we can better see what we are and where we are going — well, that might be of some help. The goal might become clearer. So I consider LSD to be of some value to some people, and practically no damage to anyone.” Bill Wilson, founder of Alcoholics Anonymous [Francis Hartigan, Bill W., Chapter 25, p. 190-197 and p. 170-171, St. Martins Press, 2000,]

The founder of alcoholics anonymous, Bill Wilson, is reported to have been treated with lysergic acid diethylamide (LSD) to help him stay abstinent from alcohol (1) and he credited it with helpful therapeutic properties. Yet the idea that illicit drugs can be used in the treatment of drug and alcohol addiction sits uncomfortably with many clinicians and researchers. It can appear paradoxical: illicit drugs are allegedly controlled due to their high abuse potential so it seems unethical to give them to people who already have a propensity for problematic alcohol and other drug use. Will they not then become addicted to the very substances that are being used to treat them? Centuries of practise and decades of research suggest that this is not the case. And now with emerging neurobiological understanding of their mechanisms, these compounds are poised to change the future of addiction treatment.

Lysergic acid diethylamide

LSD was first synthesised in 1938 from ergotamine, a chemical from the ergot fungus. LSD’s psychological effects, usually last between 6 and 12 hours and can vary greatly in content across sets and settings (2). Pharmacologically, LSD is a classic serotonergic hallucinogen, with its psychedelic effects attributed to its 5HT-2A receptor agonism (3).

In the 1950s and 60s, there was substantial research into LSD being used as a treatment for alcohol dependence (4). In recent years, this interest has been reignited. A number of review papers and one meta-analysis have reviewed studies from the height of LSD research (5-7) . The meta-analysis (6) combined the results of 6 randomised controlled trials, to assess efficacy of LSD as a treatment for alcoholism (536 participants in total). Across the studies included, 59% of active treatment participants vs. 38% of controls showed reliable improvement during the first follow up (1-2 months) and these differences were still reliable at 6 months. Whilst most research has focused on alcohol,

one study of patients addicted to opioids treated with LSD demonstrated some degree of effectiveness (8). Importantly, the first study on the acute effects of LSD on brain mechanisms

in healthy volunteers was recently published (9), which may herald a new era of medical use of the drug.

Psilocybin

Psilocybin is a compound that occurs naturally in over 200 species of mushrooms. Psilocybin mushrooms have been used as spiritual catalysts in indigenous cultures for millennia, where the mushrooms are revered as powerful spiritual sacraments that provide access to ancestors and other worlds. The effects of psilocybin last between 2-6 hours dependent on dose and individual metabolism. Psilocybin's psychedelic effects, like those of LSD, are attributable to its action as a 5HT-2A receptor agonist (10).

Psilocybin has been investigated as a tool to treat nicotine addiction (11) and alcohol dependence (12). In one study, fifteen nicotine dependent smokers were given moderate and high doses of psilocybin within a structured programme of cognitive behavioural therapy (11). At six-month follow up, twelve of the 15 participants were smoking free. At 12-month follow-up, 10 participants were still smoking abstinent. At long-term follow-up (>16 months), nine participants were still confirmed as smoking abstinent. In addition, when asked at 12-month follow-up 13 participants rated their psilocybin experiences among the five most personally meaningful and spiritually significant experiences of their lives (13). Similarly, 10 volunteers with severe alcohol use disorder were given psilocybin alongside a psychosocial intervention. A significant reduction in drinking was observed relative to pre-psilocybin levels (12). Although promising, these studies suffer from the absence of control group; however, more rigorous studies are currently underway.

Ibogaine

Ibogaine is a psychoactive, indole alkaloid which is naturally found in the rootbark of a Central African plant called *Tabernanthe Iboga*. Ibogaine produces a profound psychedelic state in which visual hallucinations, often focused on prior life events, occur and feelings of normality do not return for up to 72 hours (14). Over the past

three decades, ibogaine has received interest as a possible anti-craving and anti-withdrawal aid for drug addiction, primarily opiate and cocaine addictions (15). In the mid-1990s, the National Institute on Drug Abuse (NIDA) began a programme of research into ibogaine's potentially therapeutic effects in drug addiction (16), although this was prematurely disbanded due to concerns over potential harms. Despite this, "alternative" ibogaine treatment centres are used by people with addictions around the world (17-19) and it is estimated that over 3,000 people have taken ibogaine, chiefly as a treatment for drug addiction (18) and it is licensed as a treatment in New Zealand

No double-blind, placebo-controlled clinical trials have investigated the efficacy of ibogaine to treat addiction. There are, however, a variety of observational reports which describe the moderate success of ibogaine treating opiate and cocaine addiction/withdrawal in informal treatment settings (14, 20-23). More recently, interest has been reignited with two new observational studies taking place in Mexico and New Zealand (24, 25). These results and ongoing studies are promising, but properly controlled experimental research is much needed. Importantly, there have been some well-reported fatalities associated with ibogaine use, specifically a woman from the Netherlands, whose death contributed to the closure of the NIDA-funded research in the 1990s (14, 16). This may be due to the tradition of using ibogaine during opioid withdrawal – where there is extreme physiological reactions that might exacerbate ibogaine toxicity. Trials using patients in abstinence might be better.

Ayahuasca

Ayahuasca is an Amazonian psychoactive brew made from the *Banisteriopsis capipi* vine and the *Psychotria viridis* bush, along with a variety of other Amazonian plants (26), which produces an altered state of consciousness involving perceptual and affective changes (27). Ayahuasca is taken in religious and shamanistic settings, as well as in informal treatment centres (26). The compounds thought to be critical in its psychedelic effects are dimethyltryptamine (DMT) and monoamine oxidase inhibitors such as harmine; the latter compounds allow DMT to be active via the oral route as they block its metabolism in gut and liver (28) and then bind strongly to 5HT-2A receptors (29).

There are a variety of reports that suggest ayahuasca consumption is associated with reduced alcohol and drug problems (30-32). One recent observational study found reductions in alcohol, cocaine and tobacco use, and improvements in subjective wellbeing in a sample of 12 people who were treated with ayahuasca for drug problems (27).

Ketamine

Ketamine, an N-methyl-D-aspartate receptor (NMDAR) antagonist, when administered at sub-anaesthetic doses can lead to a psychedelic state. Researchers have attempted to incorporate this state into therapeutic interventions for addiction. Ketamine has a good safety profile with minimal impact on the respiratory system as well as a short half-life, so any psychedelic effects wear off quickly post infusion (33-35). Therefore, ketamine is an attractive drug to use in this treatment context.

One influential study demonstrated the remarkable potential for ketamine psychedelic therapy (KPT) to treat alcohol dependence (36). An impressive 66% of detoxified alcoholics were found to maintain abstinence a year after KPT as compared to only 24% of those patients who engaged with conventional treatment. However, patients were not randomised to a condition, instead they chose whether to participate in KPT or conventional treatment. These preliminary findings have been supported by case studies using ketamine and transpersonal therapy; 70% abstinence rates at one year have been shown in 15 patients (37). As ever, randomised controlled trials (RCTs) are needed to fully understand efficacy and two RCTs investigating ketamine as a treatment for alcohol dependence are currently underway. One RCT has been conducted with heroin addicts, which reported substantially greater abstinence rates following a large, 'psychedelic' dose of ketamine compared to a low, 'non-psychedelic' dose of ketamine (38). No placebo control group was used in this study, however.

Impacts of ketamine administration on cocaine abuse have also been investigated. Ketamine administration, combined with relaxation, have been shown to increase motivation to quit, decrease craving and reduce cocaine self-administration in the laboratory 24 hours post-infusion (39, 40). Interestingly, the mystical element and intensity of the experience have been shown to mediate motivation to quit (41).

Mechanisms of Action

These psychedelic drugs have plausibly different mechanistic actions, related to their specific effects on 5HT-2A or NMDA receptors. However, here, we strive for a more parsimonious explanation of the similar long-term changes in behaviour that are observed following administration of these compounds in people with problematic substance use.

Anti-depressant effects

Ketamine has emerged as a rapid acting and potent antidepressant (42) . Similarly, a small open-label trial with psilocybin has found preliminary evidence of efficacy following a single dose in treatment-resistant depressed patients (43). In healthy humans, individuals have reported long-term increases in optimism following LSD (43) and increases in wellbeing and openness following psilocybin administration (44, 45).

Depression occurs very frequently in addiction and large numbers of people with drug and alcohol problems have depressive symptoms upon entry into detoxification programmes (46, 47). Depressive symptoms also have been found to be a key factor in precipitating relapse in alcohol (48). Effects of psychedelics on depressive symptoms may explain some of their treatment effects in addiction. Psychedelic drugs may also switch off or disrupt the brain circuits involved in the ruminative style of thinking observed both in depression and in problematic substance use (49).

Neuroplasticity

One promising candidate neurobiological mechanism for the lasting changes in behaviour seen following psychedelic and dissociative drugs is the stimulation of neuroplasticity, a mechanism common to both classic hallucinogens and synthetic compounds like ketamine. As ketamine is an NMDAR antagonist, it may seem paradoxical that the drug boosts plasticity. But recent work in animals also shows that ketamine-mediated blockade of NMDARs, triggers a sequence of intracellular signalling, the phosphorylation of eukaryotic elongation factor 2 (eEF2) that results in a *de-suppression* of brain derived neurotrophic factor (BDNF) translation (50-52). Increased BDNF expression following NMDAR blockade by ketamine has been shown to potentiate synaptic responses in the CA1 and dentate gyrus fields of the rat and mouse hippocampus (52), areas crucial in learning and memory. Ketamine has been

demonstrated to increase synaptic plasticity (53) and synaptogenesis (54) at 24 hours post-infusion in rats. Ketamine also persistently enhances induction of long-term potentiation 24 hours after injection and increases the NMDAR-NR2B concentration on cell surface at rat hippocampus and medial prefrontal cortex synapses in vitro (53). Animal studies show increased plasticity and learning at 24 hours post infusion.

A limited number of studies have investigated these processes in classical hallucinogens. Single dose administration of LSD in rats induces gene transcription in the prefrontal cortex associated with increased plasticity (55). Additionally, existing studies in rats suggest that administration of DOI, a synthetic 5HT-2A agonist, enhances BDNF in the parietal cortex (56) and produces a remodelling of pyramidal cells that transiently increases the dendritic spine size in cortical neurons (57). Furthermore, ibogaine treatment reduces alcohol self-administration rats and its effects are mediated by an increase in glial cell line-neurotrophic factor [GDNF] expression (58).

Experiential changes

Across all these compounds, emerging data suggest that the intensity of the subjective effects correlate with reductions in substance use (12, 40, 59). These mystical experiences have been described by various authors as an experience of a reality surpassing normal human understanding or experience, especially a reality perceived as essential to the nature of reality, feelings of unity and interconnectedness, sacredness, peace and joy, distortion of time and space perception (45, 60, 61). Recent pilot work giving psilocybin in nicotine addiction found that mystical experiences were associated with a greater reduction in smoking (59) and in alcohol dependence, both the intensity of subjective effects and mystical experience, were associated with greater improvements (12). The mystical element of the ketamine experience and the intensity of this experience have been shown to mediate motivation to quit using cocaine (41). Importantly, there seems relative specificity for the mystical experiences as predictors, therefore this is likely not just a non-specific effect reflecting an individual's sensitivity to the drug. Psychologically, it has been suggested that the psychedelic 'spiritual awakening', can give the individual a different perspective on life and a sense of meaning (62). Long-term changes in a person's outlook (44, 45) could be critical in helping to maintain abstinence.

Conclusions

Following years of hiatus, research into psychedelic drug treatment has been reinvigorated and there is emerging evidence for the effectiveness of drugs like ketamine, LSD and psilocybin in addiction, with full trials underway. In the next 5 years clearer evidence for the use of the compounds should become available. Ayahuasca and ibogaine show promise from lower quality studies but RCTs are needed and concerns about safety, in the case of ibogaine, should be addressed.

Abuse potential of all of these compounds particularly when used therapeutically appears to be low: the serotonergic hallucinogens have not been associated with subsequent addiction (12) whereas ketamine and dissociated anaesthetics have some potential for abuse, although this has not been observed when it has been used in therapeutic settings (34). The therapeutic mechanisms of these drugs in addiction treatment remain unclear but anti-depressant effects, and the consequent stimulation of neuroplasticity, as well as positive psychological effects stemming from mystical experiences with these drugs are candidates, and of course are not mutually exclusive. This is an exciting time for research into psychedelic drugs, the evidence reviewed here suggests a potential place in modern medicine for these compounds, if we are able to overcome the historical stigma associated with this class of drugs and the immense regulatory burden that their illegal Schedule 1 status imposes.

Conflict of interest

The authors declare no competing interests.

Acknowledgements

WL, AM and CJAM are in receipt of funding from the Medical Research Council (MRC)(MR/L023032/1) which supported this research and TS was supported by an MRC Proximity to Discover Award to CJAM, TS and AM and CJAM and DN receive funding from the Beckley Foundation.

References

1. Hartigan F. Bill W.: A Biography of Alcoholics Anonymous Cofounder Bill Wilson: Macmillan; 2001.
2. Fadiman J. The Psychedelic Explorer's Guide: Safe, Therapeutic, and Sacred Journeys: Inner Traditions/Bear & Co; 2011.
3. Nichols DE. Hallucinogens. Pharmacology & therapeutics. 2004;101(2):131-81.
4. Dyck E. 'Hitting highs at rock bottom': LSD treatment for alcoholism, 1950–1970. Social History of Medicine. 2006;19(2):313-29.
5. Mangini M. Treatment of alcoholism using psychedelic drugs: a review of the program of research. Journal of psychoactive drugs. 1998;30(4):381-418.
6. Krebs TS, Johansen P-Ø. Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials. J Psychopharmacol. 2012;26(7):994-1002.
7. Bogenschutz MP, Johnson MW. Classic hallucinogens in the treatment of addictions. Prog Neuropsychopharmacol Biol Psychiatry. 2016;64:250-8.
8. Savage C, McCabe OL. Residential psychedelic (LSD) therapy for the narcotic addict: a controlled study. Arch Gen Psychiatry. 1973;28(6):808-14.
9. Carhart-Harris RL, Muthukumaraswamy S, Roseman L, Kaelen M, Droog W, Murphy K, et al. Neural correlates of the LSD experience revealed by multimodal neuroimaging. Proc Natl Acad Sci USA. 2016;113(17):4853-8.
10. Vollenweider FX, Vollenweider-Scherpenhuyzen MF, Bäbler A, Vogel H, Hell D. Psilocybin induces schizophrenia - like psychosis in humans via a serotonin - 2 agonist action. Neuroreport. 1998;9(17):3897-902.
11. Johnson MW, Garcia-Romeu A, Cosimano MP, Griffiths RR. Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. J Psychopharmacol. 2014:0269881114548296.
12. Bogenschutz MP, Forcehimes AA, Pommy JA, Wilcox CE, Barbosa P, Strassman RJ. Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. J Psychopharmacol. 2015;29(3):289-99.
13. Johnson MW, Garcia-Romeu A, Griffiths RR. Long-term follow-up of psilocybin-facilitated smoking cessation. The American journal of drug and alcohol abuse. 2016:1-6.
14. Alper KR, Lotsof HS, Frenken G, Luciano DJ, Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. The American Journal on Addictions. 1999;8(3):234-42.
15. Mačiulaitis R, Kontrimavičiūtė V, Bressolle F, Briedis V. Ibogaine, an anti-addictive drug: pharmacology and time to go further in development. A narrative review. Human & experimental toxicology. 2008;27(3):181-94.
16. Mash DC, Kovera CA, Buck BE, Norenberg MD, Shapshak P, Hearn W, et al. Medication Development of Ibogaine as a Pharmacotherapy for Drug Dependence. Annals of the New York Academy of Sciences. 1998;844(1):274-92.
17. Lotsof HS. Ibogaine in the treatment of chemical dependence disorders: Clinical perspectives. MAPS Bulletin. 1995;3:16-27.
18. Alper KR, Lotsof HS, Kaplan CD. The ibogaine medical subculture. Journal of ethnopharmacology. 2008;115(1):9-24.
19. Brown TK. Preliminary results: observational study of the long-term efficacy of ibogaine-assisted treatment in participants with opiate addiction. Multidisciplinary Association for Psychedelic Studies. 2012.
20. Sisko B. Interrupting drug dependency with ibogaine: a summary of four case histories. Multidisciplinary Assoc Psychedelic Stud. 1993;4:15-24.
21. Sheppard SG. A preliminary investigation of ibogaine: case reports and recommendations for further study. Journal of Substance Abuse Treatment. 1994;11(4):379-85.

22. Luciano D. Observations on treatment with ibogaine. *The American Journal on Addictions*. 1998;7(1):89-.
23. Brown TK. Ibogaine in the treatment of substance dependence. *Current drug abuse reviews*. 2013;6(1):3-16.
24. Mojeiko V, Brown TK, Gargour K, Jordan M. Observational study of the long-term efficacy of ibogaine-assisted treatment in participants with opiate addiction. *Multidisciplinary Association for Psychedelic Studies*. 2010.
25. Noller G. Observational study of the long-term efficacy of ibogaine-assisted treatment in participants with opioid addiction. *Multidisciplinary Association for Psychedelic Studies*. 2012.
26. Bouso JC, Riba J. *Ayahuasca and the treatment of drug addiction. The therapeutic use of ayahuasca*: Springer; 2014. p. 95-109.
27. Thomas G, Lucas P, Capler NR, Tupper KW, Martin G. Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. *Curr Drug Abuse Rev*. 2013;6(1):30-42.
28. McKenna DJ, Towers GN, Abbott F. Monoamine oxidase inhibitors in South American hallucinogenic plants: tryptamine and β -carboline constituents of ayahuasca. *Journal of ethnopharmacology*. 1984;10(2):195-223.
29. Smith RL, Canton H, Barrett RJ, Sanders-Bush E. Agonist properties of N, N-dimethyltryptamine at serotonin 5-HT 2A and 5-HT 2C receptors. *Pharmacology Biochemistry and Behavior*. 1998;61(3):323-30.
30. Doering-Silveira E, Grob CS, de Rios MD, Lopez E, Alonso LK, Tacla C, et al. Report on psychoactive drug use among adolescents using ayahuasca within a religious context. *Journal of Psychoactive Drugs*. 2005;37(2):141-4.
31. Grob CS, McKenna DJ, Callaway JC, Brito GS, Neves ES, Oberlaender G, et al. Human psychopharmacology of hoasca, a plant hallucinogen used in ritual context in Brazil. *J Nerv Ment Dis*. 1996;184(2):86-94.
32. Halpern JH, Sherwood AR, Passie T, Blackwell KC, Ruttenber AJ. Evidence of health and safety in American members of a religion who use a hallucinogenic sacrament. *Medical Science Monitor*. 2008;14(8):SR15-SR22.
33. De Luca MT, Meringolo M, Spagnolo PA, Badiani A. The role of setting for ketamine abuse: clinical and preclinical evidence. 2012.
34. Morgan, Curran HV. Ketamine use: a review. *Addiction*. 2012;107(1):27-38.
35. Perry Jr EB, Cramer JA, Cho H-S, Petrakis IL, Karper LP, Genovese A, et al. Psychiatric safety of ketamine in psychopharmacology research. *Psychopharmacology (Berl)*. 2007;192(2):253-60.
36. Krupitsky E, Grinenko A. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. *Journal of psychoactive drugs*. 1997;29(2):165-83.
37. Kolp EF, H. L; Young, M. S.; Krupitsky, E. Ketamine Enhanced Psychotherapy: Preliminary Clinical Observations on Its Effectiveness in Treating Alcoholism. *The Humanistic Psychologist*. 2006;34(4):23.
38. Krupitsky E, Burakov A, Romanova T, Dunaevsky I, Strassman R, Grinenko A. Ketamine psychotherapy for heroin addiction: immediate effects and two-year follow-up. *Journal of substance abuse treatment*. 2002;23(4):273-83.
39. Dakwar E, Hart C, Levin F, Nunes E, Foltin R. Cocaine self-administration disrupted by the N-methyl-D-aspartate receptor antagonist ketamine: a randomized, crossover trial. *Mol Psychiatry*. 2016.
40. Dakwar E, Levin F, Foltin RW, Nunes EV, Hart CL. The effects of subanesthetic ketamine infusions on motivation to quit and cue-induced craving in cocaine-dependent research volunteers. *Biol Psychiatry*. 2014;76(1):40-6.

41. Dakwar E, Anerella C, Hart C, Levin F, Mathew S, Nunes E. Therapeutic infusions of ketamine: Do the psychoactive effects matter? *Drug Alcohol Depend.* 2014;136:153-7.
42. Aan Het Rot M, Zarate CA, Charney DS, Mathew SJ. Ketamine for depression: where do we go from here? *Biol Psychiatry.* 2012;72(7):537-47.
43. Carhart-Harris RL, Bolstridge M, Rucker J, Day CM, Erritzoe D, Kaelen M, et al. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry.* 2016.
44. Griffiths RR, Richards WA, Johnson MW, McCann UD, Jesse R. Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *J Psychopharmacol.* 2008.
45. MacLean KA, Johnson MW, Griffiths RR. Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *J Psychopharmacol.* 2011;25(11):1453-61.
46. Hasin DS, Grant BF. Major depression in 6050 former drinkers: association with past alcohol dependence. *Arch Gen Psychiatry.* 2002;59(9):794-800.
47. Boden JM, Fergusson DM. Alcohol and depression. *Addiction.* 2011;106(5):906-14.
48. Witkiewitz K, Marlatt GA. Modeling the complexity of post-treatment drinking: It's a rocky road to relapse. *Clinical Psychology Review.* 2007;27(6):724-38.
49. Caselli G, Ferretti C, Leoni M, Rebecchi D, Rovetto F, Spada MM. Rumination as a predictor of drinking behaviour in alcohol abusers: A prospective study. *Addiction.* 2010;105(6):1041-8.
50. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng P-f, et al. NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. *Nature.* 2011;475(7354):91-5.
51. Gideons ES, Kavalali ET, Monteggia LM. Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. *Proc Natl Acad Sci USA.* 2014;111(23):8649-54.
52. Nosyreva E, Autry AE, Kavalali ET, Monteggia LM. Age dependence of the rapid antidepressant and synaptic effects of acute NMDA receptor blockade. *Frontiers in molecular neuroscience.* 2014;7:94.
53. Burgdorf J, Zhang X-l, Nicholson KL, Balster RL, Leander JD, Stanton PK, et al. GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. *Neuropsychopharmacology.* 2013;38(5):729-42.
54. Li N, Lee B, Liu R-J, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. *Science.* 2010;329(5994):959-64.
55. Nichols CD, Sanders-Bush E. A single dose of lysergic acid diethylamide influences gene expression patterns within the mammalian brain. 2002.
56. Vaidya VA, Marek GJ, Aghajanian GK, Duman RS. 5-HT_{2A} receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex. *The Journal of neuroscience.* 1997;17(8):2785-95.
57. Jones KA, Srivastava DP, Allen JA, Strachan RT, Roth BL, Penzes P. Rapid modulation of spine morphology by the 5-HT_{2A} serotonin receptor through kalirin-7 signaling. *Proc Natl Acad Sci USA.* 2009;106(46):19575-80.
58. He D-Y, McGough NN, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, et al. Glial cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against alcohol consumption. *The Journal of neuroscience.* 2005;25(3):619-28.
59. Garcia-Romeu A, R Griffiths R, W Johnson M. Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Current drug abuse reviews.* 2014;7(3):157-64.

60. Stace WT. *Mysticism and philosophy*. 1960.
61. Hood RW. Theory and methods in the psychological study of mysticism. *Int J Psychol Relig*. 2013;23(4):294-306.
62. Griffiths RR, Richards WA, McCann U, Jesse R. Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology (Berl)*. 2006;187(3):268-83.
59. Nutt DJ, King LA, Nichols DE (2013) Effects of Schedule I drug laws on neuroscience research and treatment innovation. *Nat Rev Neurosci*. Aug;14(8):577-85. doi: 10.1038/nrn3530. Epub 2013 Jun 12

Key references

6** A meta-analysis of six randomised controlled trials, which included a total of 536 patients, from 1966-1970 that tested the efficacy of LSD in treating alcoholism. It showed that LSD had a beneficial impact on alcohol use at the short (~1 month) and medium term (2-3 months) follow-ups. It is the only paper that attempts to quantify the therapeutic effects of LSD in addiction during the period before psychedelic research was abruptly stopped in the 1970s.

11* An open-label pilot study people testing whether psilocybin plus a structured cessation programme could reduce cigarette smoking in dependent smokers. 80% of smokers were abstinent at the 6 month follow-up, which is substantially more than is expected from current treatments (<35%).

12* An open-label pilot study testing whether psilocybin plus motivational enhancement therapy could reduce alcohol consumption in dependent drinkers. Percentage drinking and heavy drinking days fell significantly after psilocybin administration and remained low for up to 36 weeks.

17* An observational study of 12 people who received ayahuasca-assisted treatment for problematic drug use in a First Nations community in Canada. Relative to pre-treatment, alcohol, tobacco and cocaine use had reduced at 6 months follow-up. Furthermore, reports of quality of life, hopefulness, empowerment and mindfulness increased.

35** A description of long-term research into the ability of high-dose Ketamine Psychedelic Therapy to help alcoholics maintain abstinence (111 patients in ketamine group and 100 patients in control group). The ketamine group showed considerably higher levels of abstinence compared to the control group (65.8% vs. 24%). However, it was not a randomised or placebo-controlled design; participants chose whether to receive ketamine or not. Regardless, this is the first substantial piece of research into ketamine's therapeutic effects in addiction.

37* A randomised controlled trial which compared the ability of a high dose of ketamine to a low dose of ketamine (each combined with psychotherapy) in treating heroin addiction in 70 people. More than 15% of the high dose group, while less than 5% of the low dose group, were abstinent 24 months post ketamine. However, the absence of an inactive placebo is a potential weakness of the study.

38** A human laboratory study in which cocaine addicts had the opportunity to choose to smoke real cocaine or earn money 28 hours after placebo, midazolam (active placebo) and ketamine administrations. Ketamine reduced cocaine-seeking behaviour compared to midazolam (1.6 vs. 4.3 cocaine choices) and led to a 67% reduction compared to baseline levels. Furthermore, craving and use in the real world was lowered following ketamine administration for several days.